Neurosurgery Clinical Trials
A I/IIA Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke
The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.
PI: Gary K. Steinberg, MD, PhD (NCT01287936)
Familial Intracranial Aneurysm (FIA) Study
To explore genetic and environmental factors associated with the incidence of familial intracranial aneurysms. The study continues to enroll non-familial affected patients.
PI: Gary K. Steinberg, MD, PhD (NCT00071565)
Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients with 1–3 versus 4 or more Brain Metastases
PI: Steven D. Chang, MD; Co-Investigators: Judith A Murovic, MD, Griffith Harsh, MD, Gordon Li, MD, Iris C. Gibbs, MD, Scott Soltys, MD, Steve Hancock, MD (NCT01778764)
Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults
To elucidate the effects of growth hormone replacement in patients with growth hormone deficiency on cognitive function using structural and functional neuroimaging and cognitive testing.
PI: Laurence Katznelson, MD (NCT01007071)
An Open Label, Multi-Center Pasireotide Roll-Over Protocol for Patients who have Completed a Previous Novartis-sponsored Pasireotide Study and are Judged by the Investigator to Benefit from Continued Pasireotide Treatment
PI: Laurence Katznelson, MD (NCT01794793)
An Acromegaly, Open-label, Multi-center, Safety Monitoring Program for Treating Patients with SOM230 (Pasireotide) LAR who have Need to Receive Medical Therapy (ACCESS)
PI: Laurence Katznelson, MD (NCT01995734)
A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma (ReACT)
To study if adding the experimental vaccine rindopepimut (also known as CDX-110) to bevacizumab can improve progression free survival (slow the growth of tumors) in patients with relapsed EGFRvIII positive glioblastoma.
PI: Gordon Li, MD (NCT01498328)
Progesterone for the Treatment of Traumatic Brain Injury (ProTECT III)
The ProTECT study will determine if intravenous (IV) progesterone, started within 4 hours of injury and given for a total of 96 hours, is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.
Stanford PI: Jim Quinn, MD
Sub-PI: Marco Lee, MD (NCT00822900)
An International, Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (ACT IV)
PIs: Lawrence Recht, MD and Seema Nagpal, MD (NCT01480479)
A Phase I/ll Trial of Temozolomide and Hypofractionated Radiotherapy in the Treatment of Supratentorial Glioblastoma Multiforme
To determine the safety and effectiveness of 1 week versus 6 weeks of hypofractionated radiotherapy in combination with temozolomide
PI: Scott G. Soltys, MD (NCT01120639)
The Park-Reeves Syringomyelia Research Consortium
A multi-center research effort to create a disease registry of syringomyelia and chiari I malformation to study these disorders, their natural history and clinical course.
PI: Gerald Grant, MD
Bone Flap Resorption after Cranioplasty in Children: A Multicenter Retrospective Study
A multi-center, retrospective review of pediatric cranioplasty patients to determine what risk factors play a role in infection and bone flap resorption.
PI: Gerald Grant, MD
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons with Tetraplegia
To obtain preliminary device safety information and to demonstrate the feasibility of people with tetraplegia using the System to control a computer cursor and other assistive devices with their thoughts. Additionally to determine the participants’ ability to operate communication software, such as e-mail, simply by imagining the movement of their own hand. The study is invasive and requires surgery.
PI: Jaimie Henderson, MD (NCT00912041)
DuraSeal TM Exact Spine Sealant System Post-Approval Study
The purpose of this clinical trial is to compare DuraSeal Exact Spine Sealant with other fibrin sealants in preventing cerebrospinal fluid (CSF) leak after primary repair of Dura. Duraseal Spine Sealant is indicated for use as an adjunct to sutured dural repair during spinal surgery to provide watertight closure.
PI: Harminder Singh, MD; Co-PIs: Marco Lee, MD, PhD; Jason Lifshutz, MD
For questions about these clinical trials please contact our clinical trials research coordinator Maria Coburn at 650-736-9551 or email@example.com